PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Long-lasting gene therapy benefits advanced heart failure patients

Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai report promising long-term follow-up results for its single dose AAV1/SERCA2a gene therapy in advanced heart failure patients

2013-11-19
(Press-News.org) Contact information: Lauren Woods
lauren.woods@mountsinai.org
646-634-0869
The Mount Sinai Hospital / Mount Sinai School of Medicine
Long-lasting gene therapy benefits advanced heart failure patients Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai report promising long-term follow-up results for its single dose AAV1/SERCA2a gene therapy in advanced heart failure patients

Researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai reported the long-term benefits of a single dose of their gene therapy AAV1/SERCA2a in advanced heart failure patients on Nov. 19 at the American Heart Association Scientific Sessions 2013.

The new long-term follow-up results from their initial Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID 1) clinical trial found a one-time, high-dose injection of the AAV1/SERCA2a gene therapy results in the presence of the delivered SERCA2a gene up to 31 months in the cardiac tissue of heart failure patients.

In addition, study results show clinical event rates in gene therapy patients are significantly lower three years later compared to those patients receiving placebo. Also, patients experienced no negative side effects following gene therapy delivery at three-year follow-up.

"This study shows AAV1/SERCA2a gene therapy has long-lasting and beneficial effects for congestive heart failure patients allowing us to block the downward spiral of patients with severe heart failure, " says principal investigator Roger J. Hajjar, MD, Director of the Cardiovascular Research Center and the Arthur & Janet C. Ross Professor of Medicine at Icahn School of Medicine at Mount Sinai, who developed the gene therapy approach.

The gene therapy uses a modified adeno-associated viral-vector derived from a parvovirus. The one-time gene therapy is injected through the coronary arteries of heart failure patients using catheters. It works by introducing healthy SERCA2a genes into cells. The delivery of the SERCA2a gene produces SERCA2a enzymes, which helps heart cells restore their proper use of calcium.

SERCA2a is an enzyme critical for proper pumping of calcium in calcium compartments within cells. SERCA2a dysfunction or reduced expression occurs in patients with heart failure. When SERCA2a is down-regulated, calcium stays longer in the cells than it should, and it induces pathways that lead to overgrowth of new and enlarged cells. This contributes to an enlarged heart in heart failure patients.

Previously, CUPID 1 study results showed the gene therapy to be clinically safe and effective for over 12 months with improved heart function status and left ventricular function, along with a significant decrease in recurrent cardiovascular events. CUPID 1 was the first-in human clinical gene therapy randomized, double-blind study which enrolled 39 patients with advanced heart failure.

"AAV1/SERCA2a gene therapy has been proven to be a safe and effective therapeutic intervention for advanced heart failure," says Dr. Hajjar. "Our long-term results support the potential use of AAV1/SERCA2a gene therapy as a new important additional tool for treating and managing advanced heart failure patients."

This study was presented as an Oral Session (Abstract 10667): Long Term Follow-up of Patients with Advanced Heart Failure Following a Single Intracoronary Infusion of AAV1/SERCA2a.

In addition, on Nov. 19 Dr. Hajjar also presented at the AHA Scientific Sessions 2013 a Plenary talk entitled, "How the Postgenome Era Will Change the Practice of Cardiology" and discussed his work on targeted gene therapy for human heart failure.

In his Plenary talk, Dr Hajjar presented his new findings just published in the journal Science Translational Medicine on Nov. 13 that show delivery of small ubiquitin-related modifier 1 (SUMO-1), an important regulator of SERCA2a, in preclinical heart failure models improves cardiac contractility and prevents left ventricular dilatation — two major aspects of heart failure. According to Dr. Hajjar, the transition of this SUMO-1 gene therapy from pigs to humans seems likely in the short-term. Also, Dr. Hajjar revealed that development of novel cardiotropic vectors may render cardiovascular gene therapy easier and less-invasive in the near future.



INFORMATION:



Dr. Hajjar is the scientific cofounder of the company Celladon, which is developing AAV1/SERCA2a gene therapy for the treatment of heart failure. He holds equity in Celladon and receives financial compensation as a member of its advisory board.

About the Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.

For more information, visit http://www.mountsinai.org.

Find Mount Sinai on:

Facebook: http://www.facebook.com/mountsinainyc
Twitter @mountsinainyc
YouTube: http://www.youtube.com/mountsinainy



ELSE PRESS RELEASES FROM THIS DATE:

People with highly superior powers of recall also vulnerable to false memories

2013-11-19
People with highly superior powers of recall also vulnerable to false memories UCI study reveals that common distortions seem to be shared by all Irvine, Calif., Nov. 19, 2013 — People who can accurately remember details of their daily lives going back decades ...

Advanced CT imaging proves as accurate as invasive tests to assess heart blockages, study shows

2013-11-19
Advanced CT imaging proves as accurate as invasive tests to assess heart blockages, study shows Study data from 16 hospitals in 8 countries are published in the European Heart Journal An ultrafast, 320-detector computed tomography (CT) scanner that shows both ...

Monkeys can point to objects they do not report seeing

2013-11-19
Monkeys can point to objects they do not report seeing The localization and detection capabilities of monkeys dissociate much like those of humans do Are monkeys, like humans, able to ascertain where objects are located without much more than ...

Brain imaging reveals dynamic changes caused by pain medicines

2013-11-19
Brain imaging reveals dynamic changes caused by pain medicines Study suggests role for brain imaging to create personalized treatment of chronic pain ANN ARBOR, Mich. – A study in the December issue of Anesthesiology suggests a role for brain ...

Many pediatricians uncomfortable providing care to kids with genetic conditions

2013-11-19
Many pediatricians uncomfortable providing care to kids with genetic conditions New study finds general physicians order few genetic tests, don't always discuss risks and benefits; take limited family histories Ann Arbor, Mich. — Many primary care pediatricians ...

Natural compound mitigates effects of methamphetamine abuse, University of Missouri researchers find

2013-11-19
Natural compound mitigates effects of methamphetamine abuse, University of Missouri researchers find COLUMBIA, Mo. – Studies have shown that resveratrol, a natural compound found in colored vegetables, fruits and especially grapes, may minimize the ...

New models predict where E. coli strains will thrive

2013-11-19
New models predict where E. coli strains will thrive Bioengineers at the University of California, San Diego have used the genomic sequences of 55 E. coli strains to reconstruct the metabolic repertoire for each strain. Surprisingly, these reconstructions ...

UEA research reveals how farmers could mitigate nitrous oxide emissions

2013-11-19
UEA research reveals how farmers could mitigate nitrous oxide emissions Farmers may be able to help reduce emissions of the greenhouse gas nitrous oxide (N2O) by incorporating copper into crop fertilisation processes – according to new research from the University ...

Underwater 'tree rings'

2013-11-19
Underwater 'tree rings' Calcite crusts of arctic algae record 650 years of sea ice change Almost 650 years of annual change in sea-ice cover can been seen in the calcite crust growth layers of seafloor algae, says a new study from the University of Toronto Mississauga ...

Among patients with recent ACS, use of enzyme inhibitor does not reduce risk of cardiovascular event

2013-11-19
Among patients with recent ACS, use of enzyme inhibitor does not reduce risk of cardiovascular event Chicago – Stephen J. Nicholls, M.B.B.S., Ph.D., of the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, ...

LAST 30 PRESS RELEASES:

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate

Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative

Structure dictates effectiveness, safety in nanomedicine

[Press-News.org] Long-lasting gene therapy benefits advanced heart failure patients
Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai report promising long-term follow-up results for its single dose AAV1/SERCA2a gene therapy in advanced heart failure patients